Maintenance therapy with subcutaneous imsidolimab allowed all treated patients to remain flare-free throughout the GEMINI-2 study period.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab ...

GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients with a ...

Imsidolimab is a monoclonal antibody that inhibits interleukin-36 receptor signaling and is administered intravenously.

Imsidolimab is a humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor. Treatment with imsidolimab led to significant clearance of pustulation, erythema, and scaling in ...

An international consensus statement on generalized pustular psoriasis (GPP) from the International Psoriasis Council (IPC) includes the recommendation that considerations such as body surface area ...

INGELHEIM, Germany--(BUSINESS WIRE)--EFFISAYIL ™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in ...

Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...